X4 Pharmaceuticals Restructures to Focus on Mavorixafor in Chronic Neutropenia

Rare Daily Staff

Rare disease drug developer X4 Pharmaceuticals said it is restructuring its workforce and capital spending to focus efforts on advancing mavorixafor to treat people with chronic neutropenia and optimize U.S. promotion of the drug, which is already approved to treat the rare immunodeficiency WHIM syndrome.

The company is reducing its overall headcount by 43 people or approximately 30 percent. As part of the restructuring, X4 is discontinuing research efforts and closing the company’s facility in Vienna, Austria, as well as pausing pre-clinical drug candidate programs.

X4 expects its efforts will decrease annual spending by $30 to 35 million and believes it will have sufficient funds to support operations into the first half of 2026.

The decision reflects the continuing financial pressures rare disease drug developers are facing in the current financial environment. The company will also work to scale its U.S. commercial field team and supporting roles across the company while streamlining other spending to support the ongoing clinical development of mavorixafor for the larger population of those with chronic neutropenia.

Despite improving markets and X4 2024 approval of mavorixafor, which is marketed as Xolremdi, the decision shows how companies remain focused on near-term revenue opportunities and limiting spending rather than pursuing long-term development opportunities.

“This strategic restructuring is being implemented to improve our operational efficiency and capital efficiency as we continue to maximize the global market opportunity for mavorixafor and to benefit the largest number of patients we can worldwide,” said Paula Ragan, president and CEO of X4 Pharmaceuticals. “We expect this organizational redesign to sharpen our focus on the execution of our ongoing global pivotal phase 3 clinical trial of mavorixafor in chronic neutropenia while we continue to build WHIM communities through both our U.S. commercial presence and through global partnerships.”

Photo: Paula Ragan, president and CEO of X4 Pharmaceuticals